University of Medicine and Dentistry of New Jersey

Eric J Lazaro

Charles R Spillert

Corinne Devereux

William A Suval

William D Suval

This invention involves a method of analyzing a body fluid such as blood from a patient to determine whether or not there is a significant difference or change in the comparative determinants of viscosity in the body fluid sample, the comparative determinants being derived using a probe which provides increased sensitivity and corresponding improved relative viscosity values when used together with a suitable viscosity device, in order to identify the presence or incipiency of a symptomatic or asymptomatic pathology caused by or leading to said differences or changes in viscosity.

Comparative determinants of viscosity in body fluids obtained with

A method of analyzing samples of whole blood from a patient is disclosed which involves determining whether or not there is a significant difference or change in the comparative determinants of hypercoagulability in the sample. The comparative determinants are derived using two or more different detection systems, or two or more components of a single detection system, especially two or more probes, which provide variable force-induced energy inputs to the samples being measured in order to identify the presence of incipiency of a symptomatic or asymptomatic pathology caused by, or leading to, differences or changes in hypercoagulability.

Hypercoagulability comparative determinants obtained using detection

There is disclosed a method of testing, and a kit therefor, a cellular hematologic fluid derived from a mammal to determine the existence in the mammal of a pathological state or condition wherein an immunomodulator is admixed with the cellular hematologic fluid of the mammal and a reaction parameter determined and compared with known reaction parameters of cellular hematologic fluids of mammals of known healthy states to like immunomodulator. In a preferred embodiment of the present invention, the reaction parameter is a clotting parameter as determined as fibrin levels.

Method for determining the existence and/or the monitoring of a

There is disclosed a process for treating a warm-blooded animal wherein there is administered to the warm-blooded animal a therapeutically effective amount of composition selected from the group consisting of 5-methyl-3-sulfanilamidoisoxazole, a salt of 5-methyl-3-sulfanilamidoisoxazole with a pharmaceutically acceptable base, 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine, a salt of 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine with a pharmaceutically acceptable acid and mixtures thereof. The composition is useful to treat a fibrosarcoma (SAD.sub.2) tumor in warm-blooded animals.

Process for treating a warm-blooded animal with an

Method for determining the existance and/or the monitoring of a

A method of testing a cellular hematologic fluid derived from a mammal to determine the existence in the mammal of a pathological state or condition wherein an immunomodulator is admixed with the cellular hematologic fluid of the mammal and a reaction parameter determined and compared with known reaction parameters of cellular hematologic fluids of mammals of known healthy states to like immunomodulator. In a preferred embodiment of the present invention, the reaction parameter is a clotting parameter as determined as fibrin levels.

Method of determining the existence and/or the monitoring of a

There is disclosed a process for treating a warm-blooded animal to be subjected to radiotherapy or chemotherapy wherein there is administered to the warm-blooded animal a therapeutically effective amount of a composition selected from the group consisting of 5-methyl-3-sulfanilamidoisoxazole, a salt of 5-methyl-3-sulfanilamidoisoxazole with a pharmaceutically acceptable base, 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine, a salt of 2,4-diamino-5-(3,4,5-trimethoxybenzene) pyrimidine with a pharmaceutically acceptable acid and mixtures thereof.

Process for treating a warm-blooded animal to be subjected to

There is disclosed a process for treating a warm-blooded animal subjected to barbituate anesthesia to potentiate effects thereof wherein there is administered to the warm-blooded animal a therapeutically effective amount of a composition selected from the group consisting of 5-methyl-3-sulfanilamidoisoxazole, a salt of 5-methyl-3-sulfanilamidoisoxazole with a pharmaceutically acceptable base, 2,4-diamino-5-3-(3,4,5-trimethoxybenzyl) pyrimidine, a salt of 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine with a pharmaceutically acceptable acid and mixtures thereof.

Process for potentiating effects of barbituate anesthesia to a

There is disclosed a process for prolonging recalcification, prothrombin and thrombin times of human plasma which comprises administering to a warm-blooded animal a composition selected from the group consisting of 5-methyl-3-sulfanilamidoisoxazole, a salt of 5-methyl-3-sulfanilamidoisoxazole with a pharmaceutically acceptable base, 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine, a salt of 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine with a pharmaceutically acceptable acid and mixtures thereof.

Process for prolonging recalcification, prothrombin and thrombin times

There is disclosed a process for treating a warm-blooded animal following burn injury wherein there is administered to the warm-blooded animal a therapeutically effect amount of a composition selected from the group consisting of 5-methyl-3-sulfanilamidoisoxazole, a salt of 5-methyl-3-sulfanilamidoisoxazole with a pharmaceutically acceptable base, 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine, a salt of 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrmidine with a pharmaceutically acceptable acid and mixtures thereof.

Growing community of inventors

Jersey City, NJ, United States of America

Eric J Lazaro